More recently, Enhertu (fam-trastuzumab deruxtecan-nxki) has become available for the treatment of unresectable or metastatic HER2-positive breast cancer, and this drug attacks both HER2 and topoisomerase in cancer cells [48,49]. This evidence concerns the gene ERBB2 and breast carcinoma.